Teva Pharmaceutical Industries Limited (TEVA)

NYQ – Real Time Price. Currency in USD

36.74

+0.26 (0.71%)

At close: Aug 12, 2026, 3:59 PM EDT

36.44

-0.30 (-0.82%)

After-hours: Aug 12, 2026, 6:51 PM EDT

07.08.2026

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Supernus Pharmaceuticals (SUPN) and Teva Pharmaceutical Industries Ltd. (TEVA). But which of these two stocks is more attractive to value investors?

06.08.2026

Teva seeks to keep Israel ties from jury, cites Gaza war

Teva Pharmaceuticals has asked a U.S. judge to prevent insurer Humana from telling jurors it is an Israeli company at a major drug ‌price-fixing trial, arguing that strong public views over the Gaza war could prejudice proceedings and affect its ability to receive a fair hearing.

05.08.2026

Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan

Teva Pharmaceutical Industries Limited is executing a successful turnaround, driven by its "Pivot to Growth" strategy and strong innovative medicines performance. Management raised 2026 guidance for Austedo, Ajovy, and Uzedy, targeting $3.7B specialty revenue (17% y/y growth) and a robust pipeline through 2030. Generics and biosimilars remain stable, funding R&D for innovation, while margin improvements and debt reduction enhance the risk/reward profile.

03.08.2026

Teva's Re-Rating Still Has Room To Run

Teva Pharmaceutical is undergoing a transformation, shifting its revenue mix toward specialty and innovative drugs, now over $1 billion per quarter. TEVA targets $3.7 billion in specialty/innovative sales for 2026 and aims for operating margins near 30% by 2027, driven by product mix and cost savings. Leverage has dropped below 3x EBITDA, with a goal of 2x by 2027, supported by $2–$2.4 billion free cash flow guidance for 2026.

02.08.2026

Why Teva Pharmaceutical Stock Surged This Week

Teva posted its Q2 results this week, reporting an earnings miss even though sales beat expectations. The company's forward guidance didn't deliver big surprises, but it looked solid enough.

Videos

No Data

There is no data to display

Teva Pharmaceutical Industries Limited (TEVA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Teva Pharmaceutical Industries Limited (TEVA)

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

Teva seeks to keep Israel ties from jury, cites Gaza war

Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan

Teva's Re-Rating Still Has Room To Run

Why Teva Pharmaceutical Stock Surged This Week

Videos

No Data

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

Teva seeks to keep Israel ties from jury, cites Gaza war

Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan

Teva's Re-Rating Still Has Room To Run

Why Teva Pharmaceutical Stock Surged This Week

Videos

No Data

Search stocks

Teva Pharmaceutical Industries Limited (TEVA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Teva Pharmaceutical Industries Limited (TEVA)

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

Teva seeks to keep Israel ties from jury, cites Gaza war

Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan

Teva's Re-Rating Still Has Room To Run

Why Teva Pharmaceutical Stock Surged This Week

Videos

No Data

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

Teva seeks to keep Israel ties from jury, cites Gaza war

Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan

Teva's Re-Rating Still Has Room To Run

Why Teva Pharmaceutical Stock Surged This Week

Videos

No Data